Fernando Arias-Mendoza, M.D., Ph.D.
Adjunct Associate Professor of Radiology
Department: Radiology
Contact information
B6 BLOCKLEY HALL
423 GUARDIAN DRIVE
PHILADELPHIA, PA 19104-6069
423 GUARDIAN DRIVE
PHILADELPHIA, PA 19104-6069
Office: (215) 898-1805
Fax: (215) 573-2113
Fax: (215) 573-2113
Publications
Education:
MD (Doctor of Medicine)
School of Medicine, National University of Mexico, 1981.
MSc (Biochemistry)
School of Chemistry, National University of Mexico, 1987.
PhD (Biochemistry)
School of Chemistry, National University of Mexico, 1989.
Permanent linkMD (Doctor of Medicine)
School of Medicine, National University of Mexico, 1981.
MSc (Biochemistry)
School of Chemistry, National University of Mexico, 1987.
PhD (Biochemistry)
School of Chemistry, National University of Mexico, 1989.
Description of Research Expertise
I am a translational researcher with M.D. and a Ph.D. degrees, the last in Biochemistry. I am highly proficient in the noninvasive biomedical applications of nuclear magnetic resonance (NMR). With NMR, I have assessed metabolic and functional variables in isolated cells and perfused organs in vivo, as well as in tissues in situ of whole organisms including humans. The ultimate goal of my research is to test if these NMR-visible variables offer reliable information to improve treatment assignment and follow-up of human diseases, specially cancer.In regard to cancer, we know that tumors have abnormal levels of phosphomonoesters (PME). Given this, my research team optimized the noninvasive assessment of PME in tumors in situ using phosphorus NMR spectroscopic imaging. A translational contribution of this research is the substantiation of the correlation of the pretreatment PME tumor value with the outcome to first-line therapy in patients with lymphomas. To continue this research, I am proposing to test if this correlation is useful to predict the likelihood of each lymphoma patient to respond to first-line therapy. If this correlation is proven, then the pretreatment PME tumor value can be used in the clinic to risk-assign treatment in lymphoma patients.
My current research has the following six objectives. (1) Improve the quality and quantity of observable variables by in vivo NMR using current technical advances. (2) Improve NMR data analysis using advanced mathematical algorithms. (3) Elucidate the mechanism(s) by which PME tumor values correlate with response to therapy. (4) Optimize the power of PME to predict treatment outcome. (5) Extend the potential predictive value of PME to other cancers. (6) Extend this research to other diseases besides cancer.
Selected Publications
Julià-Sapé, M, Arias-Mendoza, F, Griffiths, J. R.: Clinical trials of MRS methods. eMagRes 4: 779-788, 2015.Garcia-Diaz, B., Garone, C., Barca, E., Mojahed, H., Gutierrez, P., Pizzorno, G., Tanji, K., Arias-Mendoza, F., Quinzii, C. M., Hirano, M.: Deoxynucleoside stress exacerbates the phenotype of a mouse model of mitochondrial neuro-gastrointestinal encephalopathy. Brain 137(Pt 5): 1337-49, 2014.
Arias-Mendoza, F., Payne, G. S., Zakian, K., Stubbs, M., O'Connor, O. A., Mojahed, H., Smith, M. R., Schwarz, A. J., Shukla-Dave, A., Howe, F., Poptani, H., Lee, S. C., Pettengel, R., Schuster, S. J., Cunningham, D., Heerschap, A., Glickson, J. D., Griffiths, J. R., Koutcher, J. A., Leach, M. O., Brown, T. R.: Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma. Academic Radiology 20(9): 1122-9, 2013.
Lee, S.-C., Arias-Mendoza, F., Poptani, H., Delikatny, E. J., Wasik, M., Marzec, M., Schuster, S. J., Nasta, S. D., Svoboda, J., O'Connor, O. A., Smith, M. R., Glickson, J. D.: Prediction and early detection of response by NMR spectroscopy and imaging. PET Clinics 7: 119-126, 2012.
Sonabend, A. M., Stuart, R. M., Yun, J., Yanagihara, T., Mohajed, H., Dashnaw, S., Bruce, S. S., Brown, T., Romanov, A., Sebastian, M., Arias-Mendoza, F., Bagiella, E., Canoll, P., Bruce, J. N.: Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro-Oncology 13(8): 886-93, 2011.
Arias-Mendoza, F., Payne, G. S., Zakian, K. L., Schwarz, A. J., Stubbs, M., Stoyanova, R., Ballon, D., Howe, F. A., Koutcher, J. A., Leach, M. O., Griffiths, J. R., Heerschap, A., Glickson, J. D., Nelson, S. J., Evelhoch, J. L., Charles, H. C., Brown, T. R.: In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR in Biomedicine 19(4): 504-12, 2006.
Coon, A. L., Arias-Mendoza, F., Colby, G. P., Cruz-Lobo, J., Mocco, J., Mack, W. J., Komotar, R. J., Brown, T. R., Connolly, E. S., Jr.: Correlation of cerebral metabolites with functional outcome in experimental primate stroke using in vivo 1H-magnetic resonance spectroscopy. American Journal of Neuroradiology 27(5): 1053-8, 2006.
Arias-Mendoza, F., Zakian, K., Schwartz, A., Howe, F. A., Koutcher, J. A., Leach, M. O., Griffiths, J. R., Heerschap, A., Glickson, J. D., Nelson, S. J., Evelhoch, J. L., Charles, H. C., Brown, T. R.: Methodological standardization for a multi-institutional in vivo trial of localized 31P-MR spectroscopy in human cancer research. In vitro and normal volunteer studies. NMR in Biomedicine 17(6): 382, 2004.
Arias-Mendoza, F., Smith, M. R., Brown, T. R.: Predicting treatment response in non-Hodgkin''s lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Academic Radiology 11(4): 368-76, 2004.
Franks, S., Smith, M., Arias-Mendoza, F., Shaller, C., Padavic-Shaller, K., Kappler, F., Zhang, Y., Negendank, W., Brown, T.: Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytes. Leukemia Research 26(10): 919, 2002.